March 25, 2026
At the recent LSX World Congress Europe in Lisbon, Cereno Scientific CEO Sten R. Sörensen joined industry leaders for the panel “Rare Diseases vs. Broad Indications: Where to Focus Early‑Stage Innovation.” He outlined why Cereno has chosen to begin its development pathway in rare diseases and how this strategy accelerates both scientific progress and patient impact.
Sten explained that although Cereno’s epigenetic modulation platform was initially explored for common cardiovascular conditions, rare diseases offer a more efficient route to demonstrating clinical value. Their faster disease progression enables quicker proof‑of‑concept, and smaller, focused studies allow companies to validate mechanisms with greater speed and precision. This approach also supports sustainable pricing and creates a strong foundation for later expansion into broader indications.
He noted that advances in epigenetics have revealed new therapeutic potential in older molecules, making rare diseases an ideal starting point for a “pipeline‑in‑a‑product” strategy. By proving biology in high‑need, well‑defined populations, Cereno can later extend its insights into larger cardiovascular and pulmonary disease areas.
Sten also emphasized the importance of global trial execution and deep collaboration with clinicians and patient organizations. Because rare disease populations are dispersed worldwide, Cereno’s studies span multiple continents, and patient representatives are integrated directly into the company’s global steering committee to ensure development remains aligned with real‑world needs.
Regulatory momentum is further accelerating progress. Sten highlighted recent shifts, such as the increasing acceptance of single pivotal trials and the potential for Phase IIb studies to serve as pivotal evidence, as key enablers of faster patient access. He shared examples where strong early data from Cereno’s programs led to expanded access opportunities even before later‑stage trials commenced.
He also addressed the broader pricing landscape, noting that sustainable reimbursement is essential for continued innovation and that inconsistent global pricing policies risk limiting patient access to new therapies.
Looking ahead, Sten noted that this rare‑disease‑first strategy is not only accelerating clinical progress but also strengthening Cereno’s position within the broader biopharma ecosystem. Meetings at LSX and Bio‑Europe Spring underscored how central these forums have become to the company’s partnering strategy, creating the foundation for future collaborations, licensing opportunities, and strategic transactions that can further scale impact.
Across discussions with potential partners, Cereno highlighted the continued momentum of its epigenetic HDAC inhibitor platform. CS1 is advancing toward a global Phase IIb trial in PAH, while CS014 is progressing toward Phase IIb initiation in PH‑ILD in 2027. These programs, together with growing external validation from clinical leaders and industry stakeholders, reinforce the company’s conviction in a repeatable, mechanism‑driven approach designed to modify the underlying biology of cardiopulmonary disease.
By proving the value of its platform in well‑defined rare disease populations, and by building the right global partnerships early, Cereno is positioning itself for potential expansion into multiple indications over time and ultimately deliver disease‑modifying therapies that can slow, halt, or even reverse progression for patients worldwide.
This article is based on a panel discussion held at LSX World Congress Europe on March 25, 2026, titled “Rare Diseases vs. Broad Indications: Where to Focus Early-Stage Innovation.” Panel participants included Sten R. Sörensen, CEO, Cereno Scientific; Lori Badura, VP, Head of Global Partnering Neuroscience & Rare Disease, Ipsen; Linda McGoldrick, Board Director, Alvotech; and Gražina Mykolaitytė-Nielsen, CEO & Co-Founder, VUGENE. The article primarily reflects the perspectives shared by Cereno Scientific.